Mahdy Ayman, Elmissiry Mostafa, Ghoniem Gamal
Section of Female Urology, Voiding Dysfunction and Reconstructive Surgery, Cleveland Clinic Florida, Weston, FL, 33331, USA.
Int Urogynecol J Pelvic Floor Dysfunct. 2008 Dec;19(12):1647-52. doi: 10.1007/s00192-008-0660-5. Epub 2008 Jun 5.
This study aims to evaluate the outcome of cystocele repair using Perigee with biocompatible matrix (InteXen). After IRB approval, a retrospective chart review of patients who underwent Perigee/InteXen repair was done. Success was defined as a postoperative anatomical stage 0 or I using POP-Q system. Thirty two patients were included with 14 (43.75%) who had failed previous repair. Preoperatively, eight patients (25%) had stage II cystocele, 21 (65.6%) had stage III, and three (9.4%) had stage IV. Twenty six patients (81.25%) were available for a median follow up of 8.72 (6-31) months that showed success in 25 patients (96%) with 14 (54%) having stage 0 and 11 (42%) having stage I. Complications included bladder perforation (n = 1), incidental cystotomy (n = 1), mesh erosion (n = 1), and wound dehiscence (n = 1). This study suggests cystocele repair using Perigee with InteXen has a high short-term success with lower morbidity.
本研究旨在评估使用带有生物相容性基质（InteXen）的Perigee进行膀胱膨出修补术的效果。经机构审查委员会（IRB）批准后，对接受Perigee/InteXen修补术的患者进行了回顾性病历审查。成功的定义为术后使用盆腔器官脱垂定量（POP-Q）系统处于0期或I期。共纳入32例患者，其中14例（43.75%）既往修补失败。术前，8例患者（25%）为II期膀胱膨出，21例（65.6%）为III期，3例（9.4%）为IV期。26例患者（81.25%）接受了中位时间为8.72（6 - 31）个月的随访，结果显示25例患者（96%）成功，其中14例（54%）为0期，11例（42%）为I期。并发症包括膀胱穿孔（n = 1）、意外膀胱切开术（n = 1）、补片侵蚀（n = 1）和伤口裂开（n = 1）。本研究表明，使用带有InteXen的Perigee进行膀胱膨出修补术具有较高的短期成功率且发病率较低。
